SCHEMBL1907231

SCHEMBL1907231

Cc1[c]cnn1-c1ccc(C(C)(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 1/20 0.38
S1PR4 O95977 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPT P10636 1/20 0.38
S1PR1 P21453 1/20 0.38
MAPK1 P28482 1/20 0.38
AGTR1 P30556 1/20 0.38
OPRK1 P41145 1/20 0.38
NPBWR1 P48145 1/20 0.38
MCHR1 Q99705 1/20 0.38
ADORA1 P30542 1/20 0.34
AURKA O14965 1/20 0.34
AMY1A P0DUB6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4909016 0.81 RAB9A (0.43) CYP2C9CYP2C19SMN1; SMN2ALDH1A1HTT
SCHEMBL1906253 0.78 ALDH1A1 (0.40) CYP2C9CYP2C19TSHRSMN1; SMN2KDM4E
SCHEMBL2347651 0.78 NPC1 (0.42) TSHRSMN1; SMN2ALDH1A1HTTNPC1
SCHEMBL316519 0.77 RAB9A (0.41) CYP2C19SMN1; SMN2ALDH1A1HTTNPC1
SCHEMBL316018 0.75 KMT2A (0.46) CYP2C9SMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL1908255 0.68 NPC1 (0.49) KDM4EALDH1A1HTTNPC1HSP90AA1
SCHEMBL1900876 0.67 CYP2A6 (0.45) ALDH1A1HTTMAPTHSD17B10
SCHEMBL1304888 0.67 NPBWR1 (0.39) CYP2C9CYP2C19TSHRSMN1; SMN2ALDH1A1
SCHEMBL16283450 0.67 SMN1; SMN2 (0.43) CYP2C9CYP2C19TSHRSMN1; SMN2KDM4E
SCHEMBL27514153 0.67 LMNA (0.41) TSHRSMN1; SMN2KDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 CYP2C9 4791/4885CYP2C19 4746/4885TSHR 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.